Literature DB >> 9612649

[Outcome of surgical treatment of cancer of the stomach. Report of 330 cases].

C Meyer1, S Rohr, J Vix, N De Manzini, C Bourtoul, L C Thiry.   

Abstract

The study concerned 330 cases of gastric adenocarcinoma operated from January 1969 to June 1996. Clinical, histological and therapeutic features were analyzed and compared during 3 periods (Group 1: 1969-79, Group 2: 1979-88, Group 3: 1989-96). The aim was to evaluate changes and results occurred in gastric carcinoma. The median age was 65 +/- 11 year (range 25-90), the sex ratio 2. The most common location was in the lower third of the stomach and the cancer was often far advanced (71 percent of stages III and IV). Subtotal gastrectomy was replaced by total gastrectomy and large lymph node dissection was systematically performed in group 3. Curative resection rate increased from 28 to 60 percent between group 1 and group 3. Despite the more radical surgery, post-operative mortality rates decreased respectively 22%, 9%, 8% for the groups 1, 2, 3 (p < 0.01) and global morbidity remained stable while the rate of intra-abdominal infection have changed in group 3 (4.8% vs 2.7% and 2.1% in respectively groups 1 and 2; p = ns). Two year survival rates were 20% for group 1.25% for group 2 and 35% for group 3 (p < 0.01). This results can be considered as encouraging but have to be confirmed at 5 year survival.

Entities:  

Mesh:

Year:  1997        PMID: 9612649

Source DB:  PubMed          Journal:  Chir Ital        ISSN: 0009-4773


  2 in total

1.  Subtotal or total gastrectomy for gastric cancer: impact of the surgical procedure on morbidity and prognosis--analysis of a 10-year experience.

Authors:  Ines Gockel; Sebastian Pietzka; Ursula Gönner; Gerhard Hommel; Theodor Junginger
Journal:  Langenbecks Arch Surg       Date:  2005-02-12       Impact factor: 3.445

2.  Distal gastrectomy versus total gastrectomy for distal gastric cancer.

Authors:  Zhen Liu; Fan Feng; Man Guo; Shushang Liu; Gaozan Zheng; Guanghui Xu; Xiao Lian; Daiming Fan; Hongwei Zhang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.